Humán patogén anaerob baktériumok in vitro érzékenysége tigecyclinre és a komparátor antibiotikumokra Magyarországon Prospektív, többcentrumos vizsgálat

Translated title of the contribution: In vitro sensitivity of human anaerobic pathogenic bacteria for tigecycline and comparative antibiotics in Hungary

E. Nagy, E. Urbán, Gabriella Jakab, Lenke Szikra, Cecília Miszti, J. Szabó

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

INTRODUCTION-Tigecycline, the first member of the glycylcycline family of antibiotics, is a semisynthetic derivative of minocycline. The modified tetracycline nucleus is protected against the resistance mechanisms that inactivate tetracyclines, thus tigecycline is expected to be effective against tetracycline- resistant strains. The aim of this multicenter survey, performed in 2007 and 2008 by three Hungarian laboratories, was to examine the efficiency of this drug against antianaerobic bacteria In vitro. MATERIALS AND METHODS - The participating laboratories isolated 540 strains of Gram-positive and Gram-negative anaerobic bacteria from various infectious sites. These sites represent the classes of infections for which tigecycline was recently approved as a treatment option (skin and soft tissue and intra-abdominalinfections), or for which it will be licensed in the near future (lower respiratory tract infections). Evaluation of antibiotic susceptibility was performed by Etest, and the efficiencies of six antibiotics were determined using MIC values. RESULTS - The 540 strains belonged to 33 different species. Of the 104 strains of Gram-positive anaerobic cocci, 100% proved to be susceptible to tigecycline. Similarly, 98% of the examined Clostridium strains showed susceptibility to this antibiotic. Two of the 56 Prevotella strains were resistant against tigecycline. MIC50 and MIC90 values in the 280 Bacteroides strains were 0.5 μg/ml and 1 μg/ml, respectively, whereas only 1.8% of the tested strains showed low resistance. CONCLUSION - Similarly to the findings of international surveys, our results show that tigecycline is effective against the great majority (97.4% susceptibility) of relevant anaerobic bacteria that are isolated from skin and soft tissue, intra-abdominal and lower respiratory tract infections. Thus, empiric use of tigecycline is recommended in any infections where anaerobic bacteria alone or a mixed flora of aerobic and anaerobic bacteria are likely to be present.

Original languageHungarian
Pages (from-to)593-601
Number of pages9
JournalLege Artis Medicinae
Volume19
Issue number10
Publication statusPublished - Oct 2009

Fingerprint

Anaerobic Bacteria
Hungary
Anti-Bacterial Agents
Tetracycline
Respiratory Tract Infections
Gram-Negative Anaerobic Bacteria
Disk Diffusion Antimicrobial Tests
Prevotella
Gram-Positive Cocci
Tetracyclines
Aerobic Bacteria
Skin
Minocycline
Bacteroides
Clostridium
Infection
tigecycline
In Vitro Techniques
Bacteria
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Humán patogén anaerob baktériumok in vitro érzékenysége tigecyclinre és a komparátor antibiotikumokra Magyarországon Prospektív, többcentrumos vizsgálat. / Nagy, E.; Urbán, E.; Jakab, Gabriella; Szikra, Lenke; Miszti, Cecília; Szabó, J.

In: Lege Artis Medicinae, Vol. 19, No. 10, 10.2009, p. 593-601.

Research output: Contribution to journalArticle

@article{4623623d21824aa682d31d8d286c0116,
title = "Hum{\'a}n patog{\'e}n anaerob bakt{\'e}riumok in vitro {\'e}rz{\'e}kenys{\'e}ge tigecyclinre {\'e}s a kompar{\'a}tor antibiotikumokra Magyarorsz{\'a}gon Prospekt{\'i}v, t{\"o}bbcentrumos vizsg{\'a}lat",
abstract = "INTRODUCTION-Tigecycline, the first member of the glycylcycline family of antibiotics, is a semisynthetic derivative of minocycline. The modified tetracycline nucleus is protected against the resistance mechanisms that inactivate tetracyclines, thus tigecycline is expected to be effective against tetracycline- resistant strains. The aim of this multicenter survey, performed in 2007 and 2008 by three Hungarian laboratories, was to examine the efficiency of this drug against antianaerobic bacteria In vitro. MATERIALS AND METHODS - The participating laboratories isolated 540 strains of Gram-positive and Gram-negative anaerobic bacteria from various infectious sites. These sites represent the classes of infections for which tigecycline was recently approved as a treatment option (skin and soft tissue and intra-abdominalinfections), or for which it will be licensed in the near future (lower respiratory tract infections). Evaluation of antibiotic susceptibility was performed by Etest, and the efficiencies of six antibiotics were determined using MIC values. RESULTS - The 540 strains belonged to 33 different species. Of the 104 strains of Gram-positive anaerobic cocci, 100{\%} proved to be susceptible to tigecycline. Similarly, 98{\%} of the examined Clostridium strains showed susceptibility to this antibiotic. Two of the 56 Prevotella strains were resistant against tigecycline. MIC50 and MIC90 values in the 280 Bacteroides strains were 0.5 μg/ml and 1 μg/ml, respectively, whereas only 1.8{\%} of the tested strains showed low resistance. CONCLUSION - Similarly to the findings of international surveys, our results show that tigecycline is effective against the great majority (97.4{\%} susceptibility) of relevant anaerobic bacteria that are isolated from skin and soft tissue, intra-abdominal and lower respiratory tract infections. Thus, empiric use of tigecycline is recommended in any infections where anaerobic bacteria alone or a mixed flora of aerobic and anaerobic bacteria are likely to be present.",
keywords = "Anaerobic bacteria, Antibiotic resistance, In vitro efficiency, Tigecycline",
author = "E. Nagy and E. Urb{\'a}n and Gabriella Jakab and Lenke Szikra and Cec{\'i}lia Miszti and J. Szab{\'o}",
year = "2009",
month = "10",
language = "Hungarian",
volume = "19",
pages = "593--601",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "10",

}

TY - JOUR

T1 - Humán patogén anaerob baktériumok in vitro érzékenysége tigecyclinre és a komparátor antibiotikumokra Magyarországon Prospektív, többcentrumos vizsgálat

AU - Nagy, E.

AU - Urbán, E.

AU - Jakab, Gabriella

AU - Szikra, Lenke

AU - Miszti, Cecília

AU - Szabó, J.

PY - 2009/10

Y1 - 2009/10

N2 - INTRODUCTION-Tigecycline, the first member of the glycylcycline family of antibiotics, is a semisynthetic derivative of minocycline. The modified tetracycline nucleus is protected against the resistance mechanisms that inactivate tetracyclines, thus tigecycline is expected to be effective against tetracycline- resistant strains. The aim of this multicenter survey, performed in 2007 and 2008 by three Hungarian laboratories, was to examine the efficiency of this drug against antianaerobic bacteria In vitro. MATERIALS AND METHODS - The participating laboratories isolated 540 strains of Gram-positive and Gram-negative anaerobic bacteria from various infectious sites. These sites represent the classes of infections for which tigecycline was recently approved as a treatment option (skin and soft tissue and intra-abdominalinfections), or for which it will be licensed in the near future (lower respiratory tract infections). Evaluation of antibiotic susceptibility was performed by Etest, and the efficiencies of six antibiotics were determined using MIC values. RESULTS - The 540 strains belonged to 33 different species. Of the 104 strains of Gram-positive anaerobic cocci, 100% proved to be susceptible to tigecycline. Similarly, 98% of the examined Clostridium strains showed susceptibility to this antibiotic. Two of the 56 Prevotella strains were resistant against tigecycline. MIC50 and MIC90 values in the 280 Bacteroides strains were 0.5 μg/ml and 1 μg/ml, respectively, whereas only 1.8% of the tested strains showed low resistance. CONCLUSION - Similarly to the findings of international surveys, our results show that tigecycline is effective against the great majority (97.4% susceptibility) of relevant anaerobic bacteria that are isolated from skin and soft tissue, intra-abdominal and lower respiratory tract infections. Thus, empiric use of tigecycline is recommended in any infections where anaerobic bacteria alone or a mixed flora of aerobic and anaerobic bacteria are likely to be present.

AB - INTRODUCTION-Tigecycline, the first member of the glycylcycline family of antibiotics, is a semisynthetic derivative of minocycline. The modified tetracycline nucleus is protected against the resistance mechanisms that inactivate tetracyclines, thus tigecycline is expected to be effective against tetracycline- resistant strains. The aim of this multicenter survey, performed in 2007 and 2008 by three Hungarian laboratories, was to examine the efficiency of this drug against antianaerobic bacteria In vitro. MATERIALS AND METHODS - The participating laboratories isolated 540 strains of Gram-positive and Gram-negative anaerobic bacteria from various infectious sites. These sites represent the classes of infections for which tigecycline was recently approved as a treatment option (skin and soft tissue and intra-abdominalinfections), or for which it will be licensed in the near future (lower respiratory tract infections). Evaluation of antibiotic susceptibility was performed by Etest, and the efficiencies of six antibiotics were determined using MIC values. RESULTS - The 540 strains belonged to 33 different species. Of the 104 strains of Gram-positive anaerobic cocci, 100% proved to be susceptible to tigecycline. Similarly, 98% of the examined Clostridium strains showed susceptibility to this antibiotic. Two of the 56 Prevotella strains were resistant against tigecycline. MIC50 and MIC90 values in the 280 Bacteroides strains were 0.5 μg/ml and 1 μg/ml, respectively, whereas only 1.8% of the tested strains showed low resistance. CONCLUSION - Similarly to the findings of international surveys, our results show that tigecycline is effective against the great majority (97.4% susceptibility) of relevant anaerobic bacteria that are isolated from skin and soft tissue, intra-abdominal and lower respiratory tract infections. Thus, empiric use of tigecycline is recommended in any infections where anaerobic bacteria alone or a mixed flora of aerobic and anaerobic bacteria are likely to be present.

KW - Anaerobic bacteria

KW - Antibiotic resistance

KW - In vitro efficiency

KW - Tigecycline

UR - http://www.scopus.com/inward/record.url?scp=70350442545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350442545&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:70350442545

VL - 19

SP - 593

EP - 601

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 10

ER -